Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies
- 20 May 2014
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (11), 1424-1430
- https://doi.org/10.1111/jdv.12549
Abstract
Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications for therapeutic decision-making in the management of patients with moderate-to-severe psoriasis.Keywords
Funding Information
- Pfizer Inc
- Synergy Medical
This publication has 55 references indexed in Scilit:
- Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyBritish Journal of Dermatology, 2013
- Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL studyAnnals Of The Rheumatic Diseases, 2012
- Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasisAnnales de Dermatologie et de Vénéréologie, 2012
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesArthritis Research & Therapy, 2011
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisThe New England Journal of Medicine, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2006
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004